EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
3.4000
+0.1400 (+4.29%)
At close: 4:15PM EST
Stock chart is not supported by your current browser
Previous Close3.2600
Open3.3100
Bid3.30 x 0
Ask3.40 x 0
Day's Range3.2000 - 3.4300
52 Week Range2.0400 - 6.3500
Volume977,986
Avg. Volume792,606
Market Cap483.208M
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • CNW Groupyesterday

    Specialized Security Firms Enter the Cannabis Market Space

    NEW YORK, Feb. 15, 2019 /CNW/ -- The demand for security in the cannabis sector has increased substantially as more businesses are becoming operational and as a result, companies involved in fields such as cultivation, retail, and distribution are seeking security services. Primarily, security service companies dabbling in the cannabis industry offer services such as armored transportation, surveillance, alarms, sensors, and on-site guards. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023.

  • GlobeNewswire3 days ago

    Emerald Health Therapeutics Announces Completion of Pure Sunfarms CAD$20 Million Credit Facility with Bank of Montreal and Farm Credit Canada

    OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.

  • GlobeNewswire8 days ago

    Emerald Health Therapeutics Announces Pure Sunfarms’ Selection to Supply Ontario Cannabis Store

    OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.

  • Baystreet8 days ago

    Stocks in play: Emerald Health Therapeutics, Inc.

    Announced its cannabis joint venture, Pure Sunfarms Corp, has through a competitive process been selected ...

  • ACCESSWIRE9 days ago

    Watch These Marijuana Stocks Enjoy A Boost From Today's Headlines

    As we see an increase in agricultural technology being used to increase the yield, and quality, of cannabis products, companies across the space will have greater access to inventory to distribute their products. Considering the fact that legal marijuana is becoming a reality in a large portion of the United States, Canada, and abroad, investors that have historically written off cannabis companies, are now flocking in droves with excitement. Nabis Holdings (INNPF) (NAB), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Green Growth Brands Inc (GGBXF), and The Supreme Cannabis Company (SPRWF) are four cannabis companies worth keeping on your radar on Thursday.

  • GlobeNewswire11 days ago

    Emerald Health Therapeutics Secures Proprietary Extraction Technology and  Extraction Capabilities in Agreement with Indena

    OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.

  • ACCESSWIRE12 days ago

    These 4 Marijuana Stocks Could Surpass Investor Expectations

    CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / Marijuana stocks have managed to become one of the hottest topics in the news over the course of the past few years. The fact of the matter is that previously conceived notions on cannabis are being replaced by favorable public opinions supporting all possible uses of marijuana, namely as a means of treatment for patients suffering from a myriad of ailments. Global Consortium Inc (GCGX), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Trulieve Cannabis Corp (OTC PINK: TCNNF), and OrganiGram Holdings Inc (OGRMF) are four pot stocks looking to remain on high this month.

  • GlobeNewswire17 days ago

    Emerald Health Therapeutics Announces Discharge of Litigation

    OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.

  • GlobeNewswire18 days ago

    Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US

    OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019.  The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.

  • GlobeNewswire19 days ago

    Emerald Health sees Expansion of Pure Sunfarms’ Cannabis Cultivation License to 825,000 Square Feet

    OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Announces Secondary Offering

    Emerald Health Therapeutics, Inc. (EMH.V) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).

  • ACCESSWIRElast month

    Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • Baystreet2 months ago

    5 Stocks To Watch As Cannabis Goes Global

    Did you miss out on the last cannabis boom? Don't worry. Another one may be right around ...

  • GlobeNewswire2 months ago

    Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada

    OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.

  • GlobeNewswire2 months ago

    Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

    OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.

  • GlobeNewswire3 months ago

    Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down

    OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.

  • GlobeNewswire3 months ago

    Emerald Health Therapeutics Appoints Agro-Biotech President

    VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.

  • Cannabis Stocks Are Overhyped: Buy This Instead
    The Motley Fool3 months ago

    Cannabis Stocks Are Overhyped: Buy This Instead

    The cannabis bubble has just about burst, but it's never too late to put your money in low-risk stocks like Canadian National Railway (TSX:CNR)(NYSE:CNI)

  • GlobeNewswire3 months ago

    Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.

  • ACCESSWIRE3 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...